문화기술의 융합 (The Journal of the Convergence on Culture Technology)

  • 제5권4호
  • /
  • Pages.421-429
  • /
  • 2019
  • /
  • 2384-0358(pISSN)
  • /
  • 2384-0366(eISSN)
국제문화기술진흥원 (The International Promotion Agency of Culture Technology)
권호 표지
DOI QR코드

DOI QR Code

초임계 열처리된 무 복합추출물의 장내세균총 및 장질환 예방 효과

The Prevention of Gut Microbiome and Intestinal Diseases from Supercritical Heat-treated Radish Complex Extracts

  • 김현경 (서원대학교 식품공학과)
  • 투고 : 2019.09.21
  • 심사 : 2019.10.25
  • 발행 : 2019.11.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

본 연구는 한국산 초임계 열처리된 무 복합 추출물을 이용하여 장내세균의 생육, 특히 식중독 및 위염, 장염 등 감염성 유해균과 정장효과를 나타내는 유익한 세균군의 생육에 미치는 영향을 알아보고자 하였다. 흰쥐를 3개 시험구 즉 정상대조군, Loperamide 투여군, 초임계 열처리된 무 복합추출물(HRE) 투여군 등으로 나누어 동물실험을 수행하면서 장내 유익한 세균의 생육에는 아무런 영향을 주지 않으면서 유해균의 생육을 저해함으로써 장기능 개선 및 세균성 장질환에 효과적이고 안전한 건강기능식품 조성물로도 유용하게 사용할 수 있다는 결과를 얻었다. 특히 무는 오랫동안 복용 시에도 전혀 부작용을 나타내지 않는 안전한 식품으로 장기간 꾸준히 복용하는 것에 의해 장내 세균총 및 세균성 장질환에 효과를 얻을 수 있다는 결론을 얻을 수 있었다.

The purpose of this study was to investigate the effects of intestinal bacteria on the growth of enteric bacteria, especially infectious harmful bacteria such as food poisoning, gastritis and enteritis, and the growth of beneficial bacteria. By dividing the rat into three test groups; normal control group, Loperamide-treated group, and supercritical heat-treated radish complex extracts(HRE)-treated group, animal experiments were performed to inhibit the growth of harmful bacteria without affecting the growth of beneficial bacteria in the intestine. It was found that it can be usefully used as an effective and safe health food composition for improving intestinal function and bacterial intestinal disease. In particular, it can be concluded that supercritical heat-treated radish complex extract is a safe food that does not show any side effects even when taken for a long time.

키워드

참고문헌

  1. Kim HY, "The effects of fruit and vegetable bark extract on learning ability and memory improvement," The Journal of the Convergence on Culture Technology, Vol. 4(3), pp. 261-267, 2018. http://dx.doi.org/10.17703/JCCT.2018.4.3.261.
  2. Kim DB, Ahn EY, and Kim EJ, "Improvement of insulin resistance by curcumin in high fat diet fed mice", The Journal of the Convergence on Culture Technology, Vol. 4(1), pp. 315-323, 2018. http://dx.doi.org/10.17703/JCCT.2018.4.1.315.
  3. Kim HK, "The functional effects of antimicrobaial activity and anti-inflammatory seaweed polysaccharide extracts," The Journal of the Convergence on Culture Technology, Vol. 4(2), pp. 155-163, 2018. http://dx.doi.org/10.17703/JCCT.2018.4.2.155.
  4. Guzik TJ, R. Korbut R, and Adamek-Guzik T, "Nitric oxide and superoxide in inflammation", Journal physiol pharmacol. Vol. 54(4), pp. 469-487, December 2003.
  5. Reuter S, Gupta SC, Chaturvedi MM, and Aggarwal BB, "Oxidative stress, inflammation, and cancer: How are they linked", Free radical biology and medicine, Vol. 49(11), pp. 1603-1616, December 2010. http://doi.org/10.1016/jfreeradbiomed.2010.09.006.
  6. Ley RE, Turnbaugh PJ, Klein S, Gordon JI," Microbial ecology: human gut microbes associated with obesity," Nature. Vol. 444(7122), pp. 1022-1023. December 2006. http://doi.org/10.1038/44410229.
  7. Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC, Siuzdak G, "Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites," Proc Natl Acad Sci USA, Vol. 106(10), pp. 3698-3703, March 2009. http://doi.org/10.1073/pnas.0812874106.Epub2009Feb 20.
  8. Kassinen A, Krogius-Kurikka L, Makivuokko H, Rinttila T, Paulin L, Corander J, et al., "The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects," Gastroenterology. Vol. 133(1), pp. 24-33, July 2007. http://doi.org/10.1053/j.gastro.2007.04.005.
  9. Jeffery IB, O'Toole PW, Ohman L, Claesson MJ, Deane J, Quigley EM, et al.. "An irritable bowel syndrome subtype defined by speciesspecific alterations in faecal microbiota," Gut, Vol. 61(7), pp. 997-1006, July 2012. http://doi.org/10.1136/gutjnl-2011-301501.Epub 2011 Dec 16.
  10. Rajilic-Stojanovic M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, et al,. "Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome," Gastroenterology, Vol. 141(5), pp. 1792-1801, November 2011. http://doi.org/10.1053/j.gastro.2011.07.043.Epub2011 Aug 5.
  11. Saulnier DM, Riehle K, Mistretta TA, Diaz MA, Mandal D, Raza S, et al,. "Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome," Gastroenterology.Vol. 141(5), pp. 1782-1791, November 2011. http://doi.org/10.1053/j.gastro.2011.06.072.
  12. Farup PG, Jacobsen M, Ligaarden SC, Rudi K, "Probiotics, symptoms, and gut microbiota: what are the relations? A randomized controlled trial in subjects with irritable bowel syndrome," Gastroenterol Res Pract. Vol. 2012(2012),pp. 214102. July 2012. http://doi.org/10.1155/2012/214102.Epub2012 Jul 31.
  13. Lee BJ, Bak Y,T. "Irritable bowel syndrome, gut microbiota and probiotics," J Neurogastroenterol Motil, . Vol. 17(3), pp. 252-266, July 2011; http://doi.org/10.5056/jnm.2011.17.3.252.Epub 2011 Jul 13.
  14. Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ. "A randomized, double-blind, placebo-controlled multicenter trial of saccharomyces boulardii in irritable bowel syndrome: Effect on quality of life," J Clin Gastroenterol, Vol. 45(8), pp. 679-683, Sepember 2011. http://doi.org/10.1097/MCG.ob013e318204593e.
  15. Kumura H, Tanoue Y, Tsukahara M, Tanaka T, Shimazaki K, "Screening of dairy yeast strains for probiotic applications," J Dairy Sci, Vol. 87(12), pp. 4050-4056, Sepember 2004. http://doi.org/10.3168/jds.s0022-0302(04)73546-8.
  16. Lennard-Jones JE, "Classification of inflammatory bowel disease," Scand J Gastroenterol, ., pp. 170-172. discussion 16-19. 1989. http://doi.org/10.3109/00365528909091339.
  17. Ahuja V, Tandon RK, "Inflammatory bowel disease in the Asia-Pacific area: A comparison with developed countries and regional differences," J Dig Dis, Vol. 11(3), pp. 134-147, June 2010. http://doi.org/10.1111/j.1751-2980.2010.00429.x.
  18. Baumgart DC, Sandborn WJ, "Inflammatory bowel disease:Clinical aspects and established and evolving therapies," Lancet, Vol. 369(9573), pp. 1641-1657, May 2007. http://doi.org/10.1016/s0140-6736(07)60751-x..
  19. Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, et al., "Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment," Genome Bio, . Vol. 13(9), R79, April 2012. http://doi.org/10.1186/gb-2012-13-9-r79.
  20. Tubbs AL, Liu B, Rogers TD, Sartor RB, Miao EA, "Dietary salt exacerbates experimental colitis," Journal of Immunology, Vol. 199(3), pp. 1051-1059, August 2017. http://doi.org/10.4049/jimmunol.1700356.Epub 2017 Jun 21.